Dean Lundell

Dean Lundell has more than 30 years of experience in the equity, debt and derivative markets. He is a former vice president at Merrill Lynch Capital Markets, where he was a bond trader. His experience there covered money markets, Treasuries and agencies, mortgage-backed, pass-through securities and CMOs, corporate bonds and eurobonds.

As a principal of a regional investment bank, he continued in that capacity and added derivative debt such as inverse floating rate notes, interest rate swaps and was involved in commercial loan syndication and trading.

Trading futures for his own account "upstairs" Lundell concentrated on interest rate markets such as the Treasury debt complex on the Chicago Board of Trade, and the eurodollar, Treasury bill, foreign exchange complex and equity indexes at the Chicago Mercantile Exchange. Lundell is also a licensed commodity trading advisor.

Other than articles and commentaries for Investopedia, Mr. Lundell's publishing credits include:

  • "Sun Tzu's Art of War for Traders and Investors" (McGraw-Hill, 1997)
  • "How to Become a CTA" (Chicago Mercantile Exchange)
  • Articles for Futures Magazine and SFO Magazine
  • For the consulting firm of Greenwich Associates, he has written educational booklets on the fixed-income markets, large corporate and investment banking and interest rate swaps, and foreign exchange.

Prior to his career on Wall Street, he served with the 82nd Airborne Division in Vietnam.

  • Showing 1-15 of 59 items
  • 1
  • 2
  • 3
  • 4
  • >>
  1. Options & Futures

    Careers In The Derivatives Market

    The growing interest in and complexity of these securities means opportunities for job seekers.
  2. Options & Futures

    Are Derivatives Safe For Retail Investors?

    These vehicles have gotten a bad rap in the press. Find out whether they deserve it.
  3. Stock Analysis

    Consulting The Consultants (FCN, NCI, HURN)

    We examine three consulting firms to see which offers the best returns, and which needs a consultant of its own.
  4. Stock Analysis

    There's No Crying In Investment Banking (BAC)

    Bank of America CEO Ken Lewis wants to take his ball and go home after a 32% decline in profits and brutal investment banking numbers.
  5. Stock Analysis

    Monsanto Building Momentum (MON)

    The seed producer had a tough quater but a great year - Monsanto just keeps getting better.
  6. Stock Analysis

    Research In Motion On The Move (RIMM)

    Research In Motion beat expectations for the quarter and looks strong, but will its motion ulitmateley be down - not up?
  7. Stock Analysis

    A Wolverine In The Hen House (WWW)

    The shoe business may seem sedate, but Wolverine is proof that agressive companies mean big returns - no matter the industry.
  8. Stock Analysis

    Cognos Surviving In A Cutthroat Game (COGN)

    Cognos slipped from the shadows to beat EPS estimates by a penny - are more surprises on the way?
  9. Stock Analysis

    Sometimes Hedging Isn't Enough (LEH, MER)

    Lehman Bros. beat earnings estimates by managing its hedges and expenses; Morgan Stanley missed because it forgot about the second part.
  10. Stock Analysis

    Hoisting Heavy Returns In Heavy Equipment (CAT, TEX, CNH)

    Big cranes and big tractors are impressive, but when it comes to the equipment makers, lean and mean is the key to success.
  11. Stock Analysis

    Steel Of A Deal (X, NUE, MT)

    Steel production has become an oligopoly. We examine steel's "big three" to see which one has the best potential.
  12. Stock Analysis

    'High Touch' Equals High Return (MON, MMM, ECL)

    We examine three companies responding to the backlash against hi-tech, computer-driven sales by adding the human touch.
  13. Stock Analysis

    Hunting The Headhunters (HSII, KFY, MAN, KELYA)

    From the executive suite to temps in the typing pool, these firms have it covered.
  14. Stock Analysis

    Can You Bank On European Banking? (DB, UBS, CS)

    We examine three giants of European investment banking as they attempt to move beyond their borders.
  15. Stock Analysis

    Medicine's Marketing Machines (CEPH, FRX, SHPGY)

    We examine three pharmaceutical companies known as much for their ads as they are for their treatments.
  • Showing 1-15 of 59 items
  • 1
  • 2
  • 3
  • 4
  • >>